Yarrow Bioscience Q2 FY26 net loss narrows to $6.51 million; R&D expenses rise to $4.94 million
YARW•China trial progress
GenSci continues a Phase 1 multiple-ascending-dose study of YB-101 in thyroid eye disease in China; data are expected in H2 2027.
YB-101 development updates
Yarrow initiated a Phase 2a/2b trial of YB-101 in Graves' disease; Phase 2a topline data are expected in H2 2027.
The FDA granted Fast Track designation for YB-101 in Graves' disease, and the company plans to start the Phase 2b trial in H1 2028.
Quarterly results and cash position
Yarrow posted a net loss of $6.5 million in Q2 2026, with R&D expense of $4.9 million and G&A expense of $1.8 million.
Cash and cash equivalents were $18.7 million at June 30, 2026; the company expects operations to be funded into 2028, including $100 million received in July.
